Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Origami Therapeutics

Ownership
Private
Therapeutic Areas
Neurology
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small moleculesProtein degradersProtein conformation correctors

Origami Therapeutics General Information

Origami Therapeutics is developing novel protein degraders and conformation correctors for neurodegenerative diseases. Their lead programs are in preclinical stage, with ORI-503 and ORI-113 for Huntington's Disease.

Contact Information

Website
https://origamitherapeutics.com/
Primary Industry
Biotech
Corporate Office
San Diego, California
United States

Drug Pipeline

Discovery
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Origami Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Origami Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Origami Therapeutics's complete valuation and funding history, request access »

Origami Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals